Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Sell
31
ANTX Quote, Financials, Valuation and Earnings
Last price:
$1.43
Seasonality move
:
-39.04%
Day range:
$1.34 - $1.44
52-week range:
$0.87 - $22.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.48x
Volume:
192.2K
Avg. volume:
619.3K
1-year change:
-92.37%
Market cap:
$42.4M
Revenue:
--
EPS (TTM):
-$2.04
Analysts' Opinion
-
Consensus RatingAN2 Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of --, AN2 Therapeutics has an estimated upside of 87.79% from its current price of $1.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.42.
Fair Value
-
According to the consensus of 4 analysts, AN2 Therapeutics has 87.79% upside to fair value with a price target of -- per share.
ANTX vs. S&P 500
-
Over the past 5 trading days, AN2 Therapeutics has overperformed the S&P 500 by 3.39% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AN2 Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AN2 Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter AN2 Therapeutics reported revenues of --.
Earnings Growth
-
AN2 Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AN2 Therapeutics reported earnings per share of -$0.43.
Enterprise value:
-51M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.84x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$37.4M | -$63.3M | -$64.8M | -$18.2M | -$11.8M | |
| EBITDA | -$37.4M | -$63.3M | -$64.8M | -$18.2M | -$11.8M | |
| Diluted EPS | -$4.61 | -$2.86 | -$2.04 | -$0.65 | -$0.43 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $107.3M | $126.4M | $97.7M | |
| Total Assets | -- | -- | $110M | $153.8M | $97.7M | |
| Current Liabilities | -- | -- | $4.4M | $14.8M | $10M | |
| Total Liabilities | -- | -- | $4.4M | $14.8M | $10M | |
| Total Equity | -- | -- | $105.6M | $139M | $87.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34.8M | -$43.9M | -$61.1M | -$11.8M | -$12M | |
| Cash From Investing | -$21.6M | -$37.6M | $61.9M | -$62.5M | $18.7M | |
| Cash From Financing | $69.4M | $85.3M | $51K | $66.1M | $23K | |
| Free Cash Flow | -$34.8M | -$43.9M | -$61.1M | -$11.8M | -$12M | |
ANTX
Sector
Market Cap
$42.4M
$48.6M
Price % of 52-Week High
6.39%
47.39%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-92.37%
-33.25%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.40
200-day SMA
Sell
Level
$1.82
Bollinger Bands (100)
Buy
Level
1 - 1.34
Chaikin Money Flow
Sell
Level
-21.6M
20-day SMA
Buy
Level
$1.40
Relative Strength Index (RSI14)
Buy
Level
54.99
ADX Line
Buy
Level
19.3
Williams %R
Neutral
Level
-24
50-day SMA
Buy
Level
$1.27
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-18.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Stock Forecast FAQ
In the current month, ANTX has received 0 Buy ratings 3 Hold ratings, and 1 Sell ratings. The ANTX average analyst price target in the past 3 months is --.
-
Where Will AN2 Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that AN2 Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About AN2 Therapeutics?
Analysts are divided on their view about AN2 Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that AN2 Therapeutics is a Buy and believe this share price will drop from its current level to --.
-
What Is AN2 Therapeutics's Price Target?
The price target for AN2 Therapeutics over the next 1-year time period is forecast to be -- according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is ANTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AN2 Therapeutics is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ANTX?
You can purchase shares of AN2 Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AN2 Therapeutics shares.
-
What Is The AN2 Therapeutics Share Price Today?
AN2 Therapeutics was last trading at $1.43 per share. This represents the most recent stock quote for AN2 Therapeutics. Yesterday, AN2 Therapeutics closed at $1.42 per share.
-
How To Buy AN2 Therapeutics Stock Online?
In order to purchase AN2 Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
